BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23683793)

  • 1. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.
    Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Tsoy M; Wahlgren V; Burakov A; Masalov D; Romanova TN; Palatkin V; Tyurina A; Yaroslavtseva T; Sinha R; Kosten TR
    Drug Alcohol Depend; 2013 Oct; 132(3):674-80. PubMed ID: 23683793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
    Krupitsky EM; Blokhina EA; Zvartau EE; Verbitskaya VE; Bushara EM; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Burakov AM; Masalov DV; Romanova TN; Grininko AY; Sinha R; Kosten T
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):39-46. PubMed ID: 26525620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.
    Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Slavina T; Pecoraro A; Woody GE
    Arch Gen Psychiatry; 2012 Sep; 69(9):973-81. PubMed ID: 22945623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
    Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
    Sullivan MA; Bisaga A; Mariani JJ; Glass A; Levin FR; Comer SD; Nunes EV
    Drug Alcohol Depend; 2013 Nov; 133(1):80-5. PubMed ID: 23827259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
    Bisaga A; Sullivan MA; Cheng WY; Carpenter KM; Mariani JJ; Levin FR; Raby WN; Nunes EV
    Drug Alcohol Depend; 2011 Dec; 119(1-2):e23-9. PubMed ID: 21715107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.
    Krupitsky E; Blokhina E; Zvartau E; Verbitskaya E; Lioznov D; Yaroslavtseva T; Palatkin V; Vetrova M; Bushara N; Burakov A; Masalov D; Mamontova O; Langleben D; Poole S; Gross R; Woody G
    Lancet HIV; 2019 Apr; 6(4):e221-e229. PubMed ID: 30880163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.
    Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Yaroslavtseva T; Pecoraro A; Woody G
    Am J Drug Alcohol Abuse; 2016 Sep; 42(5):614-620. PubMed ID: 27436632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
    Syed YY; Keating GM
    CNS Drugs; 2013 Oct; 27(10):851-61. PubMed ID: 24018540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The use of different forms of naltrexone in the treatment of opioid dependence].
    Krupitskiĭ EM; Zvartau EE; Blokhina EA; Woody G
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(11 Pt 2):66-72. PubMed ID: 22611701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
    Bisaga A; Sullivan MA; Glass A; Mishlen K; Pavlicova M; Haney M; Raby WN; Levin FR; Carpenter KM; Mariani JJ; Nunes EV
    Drug Alcohol Depend; 2015 Sep; 154():38-45. PubMed ID: 26187456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
    Sinha R; Kimmerling A; Doebrick C; Kosten TR
    Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
    Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
    Hermes G; Hyman SM; Fogelman N; Kosten TR; Sinha R
    Am J Addict; 2019 Nov; 28(6):480-488. PubMed ID: 31448846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Limited role of naltrexone in the treatment of opiate addiction].
    van Brussel GH
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.
    Krupitsky EM; Zvartau EE; Masalov DV; Tsoy MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
    J Subst Abuse Treat; 2006 Dec; 31(4):319-28. PubMed ID: 17084785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonist Models for Relapse Prevention and Reducing HIV Risk.
    Woody GE; Krupitsky E; Zvartau E
    J Neuroimmune Pharmacol; 2016 Sep; 11(3):401-7. PubMed ID: 26922659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings.
    Fox HC; Seo D; Tuit K; Hansen J; Kimmerling A; Morgan PT; Sinha R
    J Psychopharmacol; 2012 Jul; 26(7):958-72. PubMed ID: 22234929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependence.
    Farren CK; O'Malley S
    Am J Addict; 2002; 11(3):228-34. PubMed ID: 12202015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.